For context, tirzepatide (Mounjaro) is a dual GIP/GLP-1 receptor agonist, and semaglutide (Wegovy, Ozempic) is a GLP-1 receptor agonist
The machinery it drives inside the cell maxes out long before the receptor itself fills, so the effect can run flat-out while occupancy is still tiny (the spare-receptor effect). Retatrutide runs on this
In addition, regulatory bodies are adapting to the evolving landscape, which may facilitate faster approvals for innovative therapies
However, better depends on individual priorities
Payment method fees
The highest dose of orforglipron helped patients lose on average 10.5% of their weight, or 22.9 pounds, on average at 72 weeks, compared to 2.2% weight loss among those who took a placebo